Annual General Meeting Presentation 2017

November 17, 2017 Kerry Rowe

AGM Presentation 2017

Post navigation

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Annual General Meeting Presentation 2017

Related Posts

Quarterly Cash Flow Report

Dr David Stamler China Investor & Partnering Symposium Webcast

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference